Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 333-338

  Soria, Jaime ^a,b   Bull, Marta ^c   Mitchell, Caroline ^d   La Rosa, Alberto ^b   Dross, Sandra ^c   Kraft, Kelli ^c   Coombs, Robert ^d   Ticona, Eduardo ^a,b   Frenkel, Lisa ^c,d  

^a HOSPITAL NACIONAL DOS DE MAYO   (Peru)

^b Investigaciones Medicas en Salud INMENSA   (Peru)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERU; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIROLOGY; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MOLECULAR SEQUENCE DATA; NEVIRAPINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PERU; POLYMORPHISM, GENETIC; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIRUS SHEDDING;

EID: 84859191140     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0131     Document Type: Article

References (56)

1. Haidara A, Chamberland A, Sylla M, et al.: High level of primary drug resistance in Mali. HIV Med 2010;11(6):404-411.
2. Hoare A, Kerr SJ, Ruxrungtham K, et al.: Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One 2010;5(6):e10981.
3. Inocencio LA, Pereira AA, Sucupira MC, et al.: Brazilian Network for HIV Drug Resistance Surveillance: A survey of individuals recently diagnosed with HIV. J Int AIDS Soc 2009;12(1):20.
4. Lee CC, Sun YJ, Barkham T, and Leo YS: Primary drug resistance and transmission analysis of HIV-1 in acute and recent drug-naive seroconverters in Singapore. HIV Med 2009;10(6):370-377.
5. Rangel HR, Garzaro DJ, Torres JR, et al.: Prevalence of an-tiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela. Mem Inst Os-waldo Cruz 2009;104(3):522-525.
6. Taiwo B: Understanding transmitted HIV resistance through the experience in the USA. Int J Infect Dis 2009;13(5): 552-559.
7. Tossonian HK, Raffa JD, Grebely J, et al.: Primary drug resistance in antiretroviral-naive injection drug users. Int J Infect Dis 2009;13(5):577-583.
8. Wensing AM, van de Vijver DA, Angarano G, et al.: Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192(6):958-966.
9. Wheeler WH, Ziebell RA, Zabina H, et al.: Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 2010; 24(8):1203-1212.
10. Heneine W: When do minority drug-resistant HIV-1 variants have a major clinical impact? J Infect Dis 2010;201(5): 647-649.
11. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008;5(7):e158.
12. Metzner KJ, Giulieri SG, Knoepfel SA, et al.: Minority qua-sispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009;48(2):239-247.
13. Simen BB, Simons JF, Hullsiek KH, et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009;199(5):693-701.
14. Wittkop L, Gunthard HF, de Wolf F, et al.: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multi-cohort study. Lancet Infect Dis 2011;11(5):363-371.
15. Jakobsen MR, Tolstrup M, Sogaard OS, et al.: Transmission of HIV-1 drug-resistant variants: Prevalence and effect on treatment outcome. Clin Infect Dis 2010;50(4):566-573.
16. Johnson JA and Geretti AM: Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution. J Antimicrob Chemother 2010;65(7):1322-1326.
17. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385-394.
18. Caceres CF and Mendoza W: The national response to the HIV/AIDS epidemic in Peru: Accomplishments and gaps - a review. J Acquir Immune Defic Syndr 2009;51(Suppl 1):S60-66.
19. Peru MdSd: Guia de Tratamiento Antiretroviral. Lima, Peru, 2004.
20. WHO: Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: WHO, 2010.
21. UNAIDS: UNAIDS report on the global AIDS epidemic. 2010: Annex 1. http://www.unaids.org/documents/20101123-GlobalReport-Annexes1-em.pdf.
22. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47(2):266-285.
23. Schuurman R, Brambilla D, de Groot T, et al.: Underestimation of HIV type 1 drug resistance mutations: Results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses 2002;18(4):243-248.
24. Grant PM and Zolopa AR: The use of resistance testing in the management of HIV-1-infected patients. Curr Opin HIV AIDS 2009;4(6):474-480.
25. Gandhi RT, Wurcel A, Rosenberg ES, et al.: Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003;37(12):1693-1698.
26. Koelsch KK, Smith DM, Little SJ, et al.: Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus. AIDS 2003;17(7):F11-16.
27. Ellis GM, Page LC, Burman BE, Buskin S, and Frenkel LM: Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay. J Acquir Immune Defic Syndr 2009;51(3):283-289.
28. Beck IA, Crowell C, Kittoe R, et al.: Optimization of the ol-igonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants. J Acquir Immune Defic Syndr 2008;48(4): 418-427.
29. Beck IA, Mahalanabis M, Pepper G, et al.: Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 2002;40(4):1413-1419.
30. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, and Frenkel LM: Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, dida-nosine, and lamivudine. J Clin Microbiol 1998;36(2):569-572.
31. Ellis GM, Mahalanabis M, Beck IA, et al.: Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 2004;42(8):3670-3674.
32. Jallow S, Kaye S, Schutten M, et al.: Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J Clin Microbiol 2007;45(5):1565-1571.
33. Lalonde MS, Troyer RM, Syed AR, et al.: Sensitive oligonu-cleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007;45(8):2604-2615.
34. Vega Y, Perez-Alvarez L, Delgado E, et al.: Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1. J Clin Microbiol 2005;43(10):5301-5304.
35. Villahermosa ML, Beck I, Perez-Alvarez L, et al.: Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. J Hum Virol 2001;4(5):238-248.
36. Wagner TA, Kress CM, Beck I, et al.: Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: Comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide li-gation assay. J Clin Microbiol 2010;48(5):1555-1561.
37. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4(3):e4724.
38. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10(2):67-84.
39. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, and van der Noordaa J: Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28(3):495-503.
40. Bull ME, Learn GH, McElhone S, et al.: Monotypic human immunodeficiency virus type 1 genotypes across the uterine cervix and in blood suggest proliferation of cells with provirus. J Virol 2009;83(12):6020-6028.
41. Beck I and Frenkel L: Genotyping kits for the detection of HIV-1 pol drug-resistance mutations by an oligonucleotide ligation assay. http://depts.washington.edu/idimmweb/faculty/frenkel/OLAmanual1305april04.pdf.
42. Rhee SY, Kantor R, Katzenstein DA, et al.: HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. AIDS 2006;20(5):643-651.
43. Liu TF and Shafer RW: Web resources for HIV type 1 ge-notypic-resistance test interpretation. Clin Infect Dis 2006; 42(11):1608-1618.
44. Vingerhoets J, Tambuyzer L, Azijn H, et al.: Resistance profile of etravirine: Combined analysis of baseline geno-typic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010;24(4):503-514.
45. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, and Geretti AM: Prevalence and predictors of anti-retroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007;59(3):517-524.
46. Barreto CC, Sabino EC, Goncalez TT, et al.: Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in Sao Paulo, Brazil. Transfusion 2005;45(11): 1709-1714.
47. Escoto-Delgadillo M, Vazquez-Valls E, Ramirez-Rodriguez M, et al.: Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 2005;6(6):403-409.
48. Maia Teixeira SL, Bastos FI, Hacker MA, Guimaraes ML, and Morgado MG: Trends in drug resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. J Med Virol 2006;78(6):764-769.
49. Lama JR, Sanchez J, Suarez L, et al.: Linking HIV and anti-retroviral drug resistance surveillance in Peru: A model for a third-generation HIV sentinel surveillance. J Acquir Immune Defic Syndr 2006;42(4):501-505.
50. Rios M, Delgado E, Perez-Alvarez L, et al.: Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. J Med Virol 2007;79(6):647-656.
51. Li JZ, Paredes R, Ribaudo HJ, et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based anti-retroviral treatment failure: A systematic review and pooled analysis. JAMA 2011;305(13):1327-1335.
52. Cotte L, Trabaud MA, Tardy JC, et al.: Prediction of the vi-rological response to etravirine in clinical practice: Comparison of three genotype algorithms. J Med Virol 2009; 81(4):672-677.
53. Department of Health and Human Services: Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. 2011:1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 54.
54. Little SJ, Frost SD, Wong JK, et al.: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82(11):5510-5518.
55. Shafer RW, Rhee SY, Pillay D, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21(2):215-223.
56. Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860.